Please assess the completion status of the following clinical trial:

Trial Title: Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female age at least 18 years~2. A diagnosis of active non-infectious, non-necrotizing anterior scleritis (nodular or diffuse is acceptable)~3. Not planning to undergo elective ocular surgery during the study~4. Provide written informed consent~5. Be able and willing to follow instructions, return for all study visits, and willing to comply with all study-related instructions~6. If female and of childbearing potential; submit a urine sample and have a negative pregnancy test at Visit 1; agree to use an acceptable method of contraception during the study. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is post-menopausal (has not had a menstrual cycle for \>2 years or has laboratory evidence of a post-menopausal state). Acceptable methods of contraception include: spermicide with barrier, hormonal contraception, IUD, or surgical sterilization of partner. Complete abstinence throughout the study period also is acceptable.~Exclusion Criteria:~1. Contraindications to the use of the test articles~2. Known allergy or sensitivity to any medication used in this study, including the study medication or its components (e.g., corticosteroids)~3. For patients not taking systemic corticosteroids or immunosuppressants, any condition constituting conferring a likelihood that systemic corticosteroids or immunosuppressants would need to be started during the 56-day study period~4. For patients already taking systemic corticosteroids and/or immunosuppressants, any condition conferring a likelihood that systemic corticosteroid or immunosuppressant dosage would need to be changed during the 56-day study period~5. Intraocular pressure high enough that intraocular pressure-lowering medications are likely to be needed (≥25 mmHg or IOP\>target pressure for patients with glaucoma); and/or more than two ocular anti-hypertensive medications (prior IOP-lowering surgery is acceptable; combinations of two agents such as Cosopt or Combigan are considered two medications)~6. Glaucoma sufficiently advanced that an intraocular pressure spike would potentially put the patient at substantial risk of vision loss, per the clinician-investigator's judgment.~7. Cancer~8. Subject is planning to undergo elective surgery during the study period~9. Any active ocular infections (bacterial, viral, or fungal), active ocular inflammation other than scleritis (i.e., follicular conjunctivitis, iritis), or preauricular lymphadenopathy~10. History or diagnosis of ocular herpes or corneal lesion of suspected herpetic origin~11. Severe eyelid or ocular surface lesions impeding application of the iontophoresis applicator~12. Severe / serious ocular pathology or medical condition which may preclude study completion~13. Any condition conferring a likelihood that topical ophthalmic medications in use at baseline would need to be changed during the 56-day study period.~14. History of Stevens-Johnson Syndrome or mucous membrane pemphigoid~15. Unwilling to discontinue use of contact lenses for the duration of the study~16. Any open wounds / skin disease on the forehead where the iontophoresis return electrode will be applied~17. Pacemakers and/or any other electrical sensitive support system~18. Any significant illness or condition that could, in the investigator's or sub-investigator's opinion, be expected to interfere with the study parameters or study conduct; or put the subject at significant risk~19. Be currently pregnant, nursing, or planning a pregnancy; or woman who has a positive pregnancy test~20. Participation in an investigational drug or device study within 30 days of entering the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active treatment at day 0 and day 7 (Type: EXPERIMENTAL): Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~1. Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~2. Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~3. Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA
- Active Treatment at Day 0, Sham Treatment at Day 7 (Type: ACTIVE_COMPARATOR): Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~1. Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~2. Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~3. Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA

Based on this trial design, predict the completion outcome and termination type (if applicable).